Eris Lifesciences Q2 FY27 Results: October 26 Update

Eris Lifesciences Limited is scheduled to consider its unaudited financial results for the quarter and half-year ended September 30, 2026, on October 26, 2026. The September quarter is the company’s second quarter of FY27 and covers the period from July 1 to September 30, 2026. A company announcement also schedules an analyst and investor conference call for the same day at 4:30 PM IST. The call is intended to discuss standalone and consolidated Q2 and H1 FY27 results. The supplied information does not include the actual Q2 FY27 revenue, profit, margin, or earnings-per-share figures. As a result, investors will need to rely on the formal exchange filing for the reported numbers and management commentary.

Board meeting scheduled for October 26

The company’s board is stated to meet on October 26 to consider the Q2 FY27 financial results. This date follows earlier references that said the Q2 FY27 reporting schedule had not been confirmed as of September 16, 2026. The later board-meeting and conference-call announcements provide the basis for treating October 26 as the scheduled results date. The results are expected to cover both the standalone and consolidated unaudited financial statements. Consolidated figures are particularly relevant because the supplied material notes that consolidated profit growth was a clearer measure than standalone profit in Q1 FY27. The formal filing will also ordinarily include notes to the accounts and the half-year financial performance.

Earnings call set for 4:30 PM IST

Eris Lifesciences has scheduled its Q2 and H1 FY27 analyst and investor conference call for 4:30 PM IST on October 26. The announcement, dated October 19, 2026, said the discussion would cover unaudited results for the quarter and half-year ended September 30. The company provided a Zoom registration link and referred investors to its website for call details. An earnings call typically gives management an opportunity to explain revenue trends, margins, business priorities, and capital allocation. It also allows analysts and investors to seek clarity on operational developments. No management remarks from the October 26 call are included in the material provided.

Q1 FY27 offers the latest reported reference point

The most recent quarterly figures cited in the supplied information are for Q1 FY27. Eris Lifesciences reported revenue of Rs 873 crore for that quarter, with revenue up 15.42% sequentially and 12.97% year-on-year. Net profit for Q1 FY27 was Rs 143 crore. The company’s investor presentation reported domestic branded formulations revenue of Rs 801 crore, up 14.2% year-on-year, and consolidated profit after tax growth of 14.5% year-on-year. These numbers provide a recent reference point but are not an estimate of the September quarter’s performance.

September 2025 quarter forms the year-on-year base

For the corresponding Q2 FY26 period, Eris Lifesciences reported revenue of Rs 792 crore and profit of Rs 134 crore. These figures represent the year-on-year comparison base for Q2 FY27. Comparing the September 2026 quarter with this base will help investors assess changes in sales and profitability over a full year. The supplied material does not provide verified consensus estimates for Q2 FY27 revenue or profit. It specifically cautions against treating unverified numerical previews as confirmed expectations. Therefore, no projected Q2 FY27 financial figure is used here.

Key reported figures at a glance

FY27 guidance frames the discussion

Eris Lifesciences has outlined FY27 revenue growth guidance of 18% to 20%, while targeting stable EBITDA margins. The company has also said it aims to grow at 1.3 times the CVM. The supplied information identifies the planned in-sourcing of Sundae Pens from Q2 FY27 as an operational initiative intended to improve cost efficiency and supply-chain control. It also refers to in-house manufacturing for its diabetes drug semaglutide in the second half of FY27, replacing outsourced supply. These initiatives may be relevant topics during the results call, although their financial contribution for Q2 has not been disclosed in the supplied material.

Margins, leverage and capital expenditure remain relevant

The Q1 FY27 material stated that margins eased to 34% from 36% a year earlier. It also flagged leverage as a constraint. The company has guided for capital expenditure of Rs 750 crore to Rs 800 crore over FY26 to FY28. Its longer-term ambition includes reaching Rs 1,000 crore of international revenue by FY30, according to the supplied information. Investors may look for an update on how these investment plans, manufacturing initiatives, and international business plans are progressing. However, any assessment of their current financial effect should await the official Q2 FY27 disclosure.

What investors can track in the filing

The October 26 filing will allow investors to compare Q2 FY27 revenue and profit with both Q1 FY27 and Q2 FY26. Management’s explanation of EBITDA margin movement will be important given the reported Q1 margin decline. Commentary on domestic branded formulations, the Sundae Pens in-sourcing plan, and semaglutide manufacturing may provide operating context. The call may also clarify the status of capex plans and the company’s FY27 growth guidance. Until the results and call disclosures are available, the confirmed information is limited to the scheduled board meeting, the 4:30 PM IST investor call, and previously reported financial data.

Conclusion

Eris Lifesciences is scheduled to release its Q2 and H1 FY27 unaudited results on October 26, 2026, with an investor call set for later that day. The reported figures will be measured against Q1 FY27 revenue of Rs 873 crore and profit of Rs 143 crore, and the Q2 FY26 base of Rs 792 crore revenue and Rs 134 crore profit. The company’s formal exchange filing and management call are the next confirmed sources for detailed financial and operational updates.